HUP0003256A3 - Use of pentosan polysulfate for preparing medicament useful in treating chronic progressive vascular scarring diseases - Google Patents

Use of pentosan polysulfate for preparing medicament useful in treating chronic progressive vascular scarring diseases

Info

Publication number
HUP0003256A3
HUP0003256A3 HU0003256A HUP0003256A HUP0003256A3 HU P0003256 A3 HUP0003256 A3 HU P0003256A3 HU 0003256 A HU0003256 A HU 0003256A HU P0003256 A HUP0003256 A HU P0003256A HU P0003256 A3 HUP0003256 A3 HU P0003256A3
Authority
HU
Hungary
Prior art keywords
treating chronic
pentosan polysulfate
medicament useful
chronic progressive
preparing medicament
Prior art date
Application number
HU0003256A
Other languages
English (en)
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25283204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0003256(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health filed Critical Us Health
Publication of HUP0003256A2 publication Critical patent/HUP0003256A2/hu
Publication of HUP0003256A3 publication Critical patent/HUP0003256A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU0003256A 1997-04-16 1998-04-10 Use of pentosan polysulfate for preparing medicament useful in treating chronic progressive vascular scarring diseases HUP0003256A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/840,777 US20010005720A1 (en) 1995-06-07 1997-04-16 Method of treating chronic progressive vascular scarring diseases

Publications (2)

Publication Number Publication Date
HUP0003256A2 HUP0003256A2 (hu) 2001-02-28
HUP0003256A3 true HUP0003256A3 (en) 2001-12-28

Family

ID=25283204

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003256A HUP0003256A3 (en) 1997-04-16 1998-04-10 Use of pentosan polysulfate for preparing medicament useful in treating chronic progressive vascular scarring diseases

Country Status (17)

Country Link
US (1) US20010005720A1 (hu)
EP (1) EP0986392A4 (hu)
JP (1) JPH1149802A (hu)
KR (1) KR20010006511A (hu)
CN (1) CN1259871A (hu)
AR (1) AR008559A1 (hu)
AU (1) AU750182B2 (hu)
BR (1) BR9809396A (hu)
CA (1) CA2285950A1 (hu)
HU (1) HUP0003256A3 (hu)
IL (1) IL132389A0 (hu)
NO (1) NO995024L (hu)
NZ (1) NZ500527A (hu)
SK (1) SK142599A3 (hu)
TW (1) TW557213B (hu)
WO (1) WO1998046237A1 (hu)
ZA (1) ZA982246B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583079A1 (en) * 2004-10-01 2006-04-13 Keryx Biopharmaceuticals, Inc. Methods using glycosaminoglycans for the treatment of kidney disease
US9339524B2 (en) 2009-03-11 2016-05-17 Jellice Co., Ltd. Drug inhibiting the progression of atherosclerosis, preventive drug, blood cholesterol-lowering drug, functional food, and specific health food
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
AU2017321817B2 (en) 2016-08-31 2022-12-15 Oji Holdings Corporation Production method for acidic xylooligosaccharide, and acidic xylooligosaccharide
JP6225321B1 (ja) 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
SG11201911318SA (en) 2017-05-31 2020-01-30 Oji Holdings Corp Moisturizing topical preparation
WO2019054344A1 (ja) 2017-09-12 2019-03-21 王子ホールディングス株式会社 ポリ硫酸ペントサン及びポリ硫酸ペントサンの製造方法
CN111511773B (zh) 2017-12-20 2023-01-13 王子控股株式会社 戊聚糖多硫酸酯以及含有戊聚糖多硫酸酯的药物
WO2023070164A1 (en) * 2021-10-28 2023-05-04 Paradigm Biopharmaceuticals Ltd Treatment of heart failure with preserved ejection fraction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US5643892A (en) * 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
HUP0003256A2 (hu) 2001-02-28
WO1998046237A1 (en) 1998-10-22
EP0986392A4 (en) 2000-04-26
EP0986392A1 (en) 2000-03-22
TW557213B (en) 2003-10-11
NO995024D0 (no) 1999-10-15
JPH1149802A (ja) 1999-02-23
US20010005720A1 (en) 2001-06-28
KR20010006511A (ko) 2001-01-26
AU7248298A (en) 1998-11-11
AR008559A1 (es) 2000-01-19
ZA982246B (en) 1998-09-17
CA2285950A1 (en) 1998-10-22
IL132389A0 (en) 2001-03-19
CN1259871A (zh) 2000-07-12
NO995024L (no) 1999-12-13
NZ500527A (en) 2001-10-26
AU750182B2 (en) 2002-07-11
BR9809396A (pt) 2000-06-13
SK142599A3 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
NZ517659A (en) Pharmaceutical delivery system for enhanced absorption of hydrophilic therapeutic agents
EP1231864A4 (en) Tissue-Attachable Drug Applicator and Method of Use Thereof
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
AU5977401A (en) Delivery devices for treatment of vascular disease
EP1600168A3 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
HK1009939A1 (en) Medicament for treating cardiac inflammatory diseases
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
AU1227302A (en) System and method for optimizing drug therapy for the treatment of diseases
IL130784A0 (en) Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with immune complex disease and pharmaceutical compositions containing the same
HUP0003256A3 (en) Use of pentosan polysulfate for preparing medicament useful in treating chronic progressive vascular scarring diseases
GB2368525B (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
HUP0104116A3 (en) Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
SI1176976T2 (sl) Uporaba LH, dajanega v srednji ali pozni folikularni fazi, za zdravljenje anovulatornih žensk
HK1022269A1 (en) Use of 1-hydroxy-2-pyridones in the manufacture of a medicament for treating skin infections
IL121217A (en) Pharmaceutical compositions containing pentosan polysulfate for treating chronic progressive vascular diseases
IL119459A0 (en) Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
SE9902597D0 (sv) New use
IL142581A (en) Medicament for treating heart disease
PT879054E (pt) Aplicação de derivados de pirrolidina na preparação de medicamentos para o tratamento do abuso de drogas
WO2000043028A3 (en) Method of treating chronic cardiac disease
HK1005497A1 (en) Use of pentosan polysulfate for the resolution of scars in chronic progressive vascular diseases
AU2380097A (en) Combination of cis-4-hydroxy-l-proline and n-methyl-cis-4-hydroxy-l-proline for use as a therapeutic agent, in particular in cancer treatment
PL328924A1 (en) Method of treating abuse of substances
EP1221945A4 (en) METHOD AND PHARMACEUTICAL AND THERAPEUTIC COMPOSITIONS FOR THE ADMINISTRATION OF ADENOSINE
AU2001245298A1 (en) Use of pentosan polysulfate for the manufacture of a medicament for the treatment of male chronic pelvic pain syndrome